Melphalan

Drug Overview

Melphalan is an alkylating agent that has been a mainstay in cancer treatment for decades. It is considered a non-specific cytotoxic agent, meaning it affects rapidly dividing cells, including cancer cells.

• Generic Name: Melphalan
• US Brand Names: Alkeran (oral and injection), Evomela (melphalan hydrochloride injection)
• Drug Class: Nitrogen Mustard Alkylating Agent (Cytotoxic Chemotherapy)
• Route of Administration: Oral (Tablet) and Intravenous (IV Injection/Infusion)
• FDA Approval Status: Approved

What Is It and How Does It Work? (Mechanism of Action)

Melphalan’s anticancer activity is based on its function as a bifunctional alkylating agent. This class of chemotherapy is not a “Targeted Therapy” but a traditional cytotoxic agent.

At the molecular level, melphalan contains a highly reactive chloroethylamine group, which allows it to form covalent bonds with nucleophilic sites in biologically critical molecules, most notably the DNA of cancer cells. The primary mechanism involves the formation of an ethylene immonium intermediate. This intermediate then reacts with the N7 position of guanine bases in the DNA strands.

Because melphalan is bifunctional (having two reactive groups), it can alkylate two separate guanine residues. This results in:

• Intrastrand and Interstrand Cross-links: The formation of chemical bridges between two nitrogen bases on the same DNA strand (intrastrand) or, more importantly, between opposing strands of the DNA helix (interstrand cross-links).
• DNA Strand Scission: The subsequent destabilization of the DNA backbone.

These cross-links physically prevent DNA replication and transcription, which are essential processes for cell division and survival. The cell recognizes this irreparable DNA damage and often initiates apoptosis (programmed cell death), leading to a reduction in the cancer cell population. This mechanism is most effective against cells that are actively proliferating, which is a characteristic of many cancer cells.

FDA Approved Clinical Indications

Oncological Uses

• Multiple Myeloma: Used alone or in combination with other agents for the palliative treatment of multiple myeloma.
• Conditioning Regimen: High-dose melphalan is a standard preparative regimen, often combined with autologous stem cell support, for patients with multiple myeloma and neuroblastoma.
• Ovarian Cancer: Approved for the palliative treatment of epithelial ovarian cancer.
• Regional Perfusion: Used in isolated limb perfusion for the treatment of certain advanced melanomas and soft tissue sarcomas.

Non-oncological Uses

• There are no currently approved non-oncological indications for melphalan.

Dosage and Administration Protocols

The dosage of melphalan is highly dependent on the specific indication, whether it is standard-dose therapy or high-dose conditioning, and the patient’s body surface area (BSA).

Dose Adjustments for Organ Dysfunction:

• Renal Insufficiency: Dosage must be reduced in patients with moderate to severe renal impairment (Creatinine Clearance <50 mL/min), particularly for IV high-dose regimens, due to decreased clearance and risk of heightened myelosuppression.
• Hepatic Insufficiency: Specific guidelines for dose adjustment are not standardized, but caution and close monitoring are warranted.

Clinical Efficacy and Research Results

Melphalan’s primary use in modern oncology is as part of the preparative regimen for autologous stem cell transplantation (ASCT) in multiple myeloma. Recent research (2020-2025) continues to affirm its role.

• Multiple Myeloma (ASCT): High-dose melphalan (e.g., 200 mg/m²) remains the backbone of ASCT conditioning. Studies consistently show that high-dose melphalan-based ASCT achieves deep responses (e.g., complete response, CR) and significantly prolongs Progression-Free Survival (PFS) compared to standard chemotherapy alone in eligible patients. A 2022 meta-analysis confirmed that, despite the advent of novel agents, ASCT with melphalan conditioning provides a robust median PFS often exceeding 4-5 years in newly diagnosed patients.
• Combination Therapies: Melphalan’s efficacy has been enhanced by combining it with novel agents. For instance, studies on the addition of melphalan to immunomodulatory drugs (IMiDs) like lenalidomide have demonstrated higher overall response rates (ORR) and deeper molecular responses than melphalan monotherapy.

Safety Profile and Side Effects

Black Box Warning

Melphalan is a highly potent cytotoxic agent. Severe bone marrow suppression (myelosuppression) resulting in infection, bleeding, or symptomatic anemia is the most significant acute toxicity and the dose-limiting factor. Secondary malignancy, particularly acute nonlymphocytic leukemia (ANLL), has been reported, especially with long-term, chronic use.

Common Side Effects (>10%)

Serious Adverse Events

• Profound Myelosuppression: Can be life-threatening, requiring hospitalization and supportive care.
• Hepatic Toxicity: Liver function abnormalities and, rarely, veno-occlusive disease (VOD) of the liver (especially with high-dose therapy).
• Hypersensitivity/Anaphylaxis (IV): Rare but serious allergic reaction; requires immediate cessation of infusion and emergency care.
• Pulmonary Fibrosis: Rare, chronic lung damage, particularly with long-term therapy.

Connection to Stem Cell and Regenerative Medicine

Melphalan is fundamentally linked to regenerative medicine through its use in Autologous Stem Cell Transplantation (ASCT). The high-dose melphalan regimen functions to ablate (destroy) the patient’s existing bone marrow, including the cancerous cells. Following this ablative therapy, the patient’s previously collected and healthy hematopoietic stem cells are infused (regenerative component) to rescue the patient from the life-threatening effects of myelosuppression and “regenerate” a functional blood and immune system. Melphalan’s role is therefore essential as the preparative agent to create the biological space for the regenerative process to occur.

Patient Management and Practical Recommendations

Pre-treatment Tests to Be Performed

• Complete Blood Count (CBC) with Differential: To establish baseline counts and assess pre-existing myelosuppression.
• Comprehensive Metabolic Panel (CMP): To evaluate baseline renal and hepatic function (BUN, Creatinine, LFTs).
• Pregnancy Test: For women of childbearing potential, as melphalan is teratogenic.
• Echocardiogram/MUGA Scan: If high-dose therapy is planned or in patients with pre-existing cardiac issues.

Precautions During Treatment

• Infection Risk: Patients are at high risk of infection due to neutropenia; meticulous hygiene and avoidance of crowded/sick individuals are critical.
• Hydration: Maintain good oral and IV hydration, especially with high-dose IV regimens, to minimize potential renal toxicity.
• Contraception: Use effective barrier or hormonal contraception during and for a period after treatment, as the drug is mutagenic and teratogenic.

“Do’s and Don’ts” List

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status, local regulatory guidelines, and investigator-specific protocols. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions and treatment plans. The information contained herein is based on general medical literature and should be used only as a supplement to, and not a substitute for, the advice of a trained physician.